The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

0%Dividend Yield

Sep 26

$0.09

Jun 26

$0.09

Mar 26

$0.09

Dec 25

$0.09

Sep 25

$0.09

10Y Growth

N/A

5Y Growth

21.18%

3Y Growth

2.91%

1Y Growth

-25%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Moderna

MRNA

Mkt Cap58.11B

Moderna, Inc. focuses on mRNA-based therapies, directly competing in the biotech space for treatments and vaccines, similar to GERM's focus on advanced treatments.

BioNTech

BNTX

Mkt Cap26.06B

BioNTech SE specializes in personalized immunotherapies, which overlaps with GERM's advancements in treatment technologies.

Pfizer

PFE

Mkt Cap162.16B

Pfizer Inc. has a broad portfolio in healthcare, including treatments and vaccines that compete with GERM's product offerings.

Novavax

NVAX

Mkt Cap1.69B

Novavax, Inc. is involved in the development of vaccines, competing in the same space as GERM's focus on treatment and prevention.

Gilead Sciences

GILD

Mkt Cap187.23B

Gilead Sciences, Inc. is known for its antiviral drugs, directly competing with GERM's advancements in treatments.

Regeneron Pharmaceuticals

REGN

Mkt Cap85.22B

Regeneron Pharmaceuticals, Inc. works on biopharmaceuticals, including treatments that could rival GERM's innovative therapies.

Abbvie

ABBV

Mkt Cap453.19B

AbbVie Inc. operates in the pharmaceuticals sector, with a focus on advanced therapies that could compete with GERM's product line.

Johnson & Johnson

JNJ

Mkt Cap663.28B

Johnson & Johnson has a diverse healthcare portfolio, including pharmaceuticals that could compete with GERM's treatments.

AMGEN

AMGN

Mkt Cap236.38B

Amgen Inc. focuses on human therapeutics, which could compete with GERM's advancements in treatment technologies.

Astrazeneca

AZN

Mkt Cap252.33B

AstraZeneca PLC has a wide range of pharmaceutical products, including treatments and vaccines that could compete with GERM's offerings.

Holdings

Regions

Sectors

About

Miscellaneous

Investment Trusts/Mutual Funds

The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

CEO

Country

United States

ISIN

US0321085815

Listings

0 Comments

Share your thoughts

FAQ

What is Amplify Treatments Testing and Advancements stock price today?▼

The current price of GERM is $19.17 USD — it has increased by +0% in the past 24 hours. Watch Amplify Treatments Testing and Advancements stock price performance more closely on the chart.

What is Amplify Treatments Testing and Advancements stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Amplify Treatments Testing and Advancements stocks are traded under the ticker GERM.

Does Amplify Treatments Testing and Advancements pay dividends?▼

Yes, GERM dividends are paid quarterly. The last dividend per share was 0.09 . As of today, Dividend Yield (FWD)% is 0%.

In which sector is Amplify Treatments Testing and Advancements located?▼

Amplify Treatments Testing and Advancements operates in the Other sector.

When did Amplify Treatments Testing and Advancements complete a stock split?▼

Amplify Treatments Testing and Advancements has not had any recent stock splits.